Siyuan Guo

Assistant Professor

Virginia Commonwealth University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Siyuan Guo is an Assistant Professor at the University of South Carolina, USA. His research encompasses areas such as the clinical implications of HIV infection on COVID-19 outcomes, mental health issues among US veterans with chronic headache disorders, and advanced statistical models for analyzing cross-sectional data in pregnancy attempts. His recent publications reflect a strong focus on public health and epidemiological studies.

Articles (7)

In studying the association between clinical measurements and time‐to‐event outcomes within a cure model, utilizing repeated observations rather than solely baseline values may lead to more accurate estimation. However, there are two main challenges in this context. First, longitudinal measurements are usually observed at discrete time points and second, for diseases that respond well to treatment, a high censoring proportion may occur by the end of the trial. In this article, we propose a joint modelling approach to simultaneously study the longitudinal observations and time‐to‐event outcome with an assumed cure fraction. We employ the functional principal components analysis (FPCA) to model the longitudinal data, offering flexibility by not assuming a specific form for the longitudinal curve. We used a Cox's proportional hazards mixture cure model to study the survival outcome. To investigate the longitudinal binary observations, we adopt a quasi‐likelihood method which builds pseudo normal distribution for the binary data and use the E‐M algorithm to estimate the parameters. The tuning parameters are selected using the Akaike information criterion. Our proposed method is evaluated through extensive simulation studies and applied to a clinical trial data to study the relationship between the longitudinal prostate specific antigen (PSA) measurements and overall survival in men with metastatic prostate cancer.

Year:

2024

Motivated by improving the prediction of the human immunodeficiency virus (HIV) suppression status using electronic health records (EHR) data, we propose a functional multivariable logistic regression model, which accounts for the longitudinal binary process and continuous process simultaneously. Specifically, the longitudinal measurements for either binary or continuous variables are modeled by functional principal components analysis, and their corresponding functional principal component scores are used to build a logistic regression model for prediction. The longitudinal binary data are linked to underlying Gaussian processes. The estimation is done using penalized spline for the longitudinal continuous and binary data. Group‐lasso is used to select longitudinal processes, and the multivariate functional principal components analysis is proposed to revise functional principal component scores with the correlation. The method is evaluated via comprehensive simulation studies and then applied to predict viral suppression using EHR data for people living with HIV in South Carolina.

Year:

2024

Purpose: HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated with abiraterone or enzalutamide. Experimental Design: We conducted a retrospective analysis of the multicenter prospective PROPHECY trial of mCRPC men (NCT02269982, n = 118) treated with abiraterone/enzalutamide. CTC detection and HOXB13 complementary DNA (cDNA) expression was measured using a modified Adnatest, grouping patients into 3 categories: CTC 0 (undetectable); CTC + HOXB13 CTC low ( + HOXB13 CTC high. The HOXB13 threshold was determined by maximally selected rank statistics for prognostic associations with overall survival (OS) and progression-free survival (PFS). Results: We included 102 men with sufficient CTC HOXB13 cDNA, identifying 25%, 31%, and 44% of patients who were CTC 0, CTC + HOXB13 low, and CTC + HOXB13 high, respectively. Median OS were 25.7, 27.8, and 12.1 months whereas the median PFS were 9.0, 7.7, and 3.8 months, respectively. In subgroup analysis among men with CellSearch CTCs ≥5 copies/mL and adjusting for prior abi/enza treatment and Halabi clinical risk score, the multivariate HR for HOXB13 CTC detection was 2.39 (95% CI, 1.06–5.40) for OS and 2.78 (95% CI, 1.38–5.59) for PFS, respectively. Low HOXB13 CTC detection was associated with lower CTC PSA, PSMA, AR-FL, and AR-V7 detection, and more liver/lung metastases (41% vs. 25%). Conclusions: Higher CTC HOXB13 expression is associated with AR-dependent biomarkers in CTCs and is adversely prognostic in the context of potent AR inhibition in men with mCRPC.

Year:

2024

Purpose: HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated with abiraterone or enzalutamide. Experimental Design: We conducted a retrospective analysis of the multicenter prospective PROPHECY trial of mCRPC men (NCT02269982, n = 118) treated with abiraterone/enzalutamide. CTC detection and HOXB13 complementary DNA (cDNA) expression was measured using a modified Adnatest, grouping patients into 3 categories: CTC 0 (undetectable); CTC + HOXB13 CTC low ( + HOXB13 CTC high. The HOXB13 threshold was determined by maximally selected rank statistics for prognostic associations with overall survival (OS) and progression-free survival (PFS). Results: We included 102 men with sufficient CTC HOXB13 cDNA, identifying 25%, 31%, and 44% of patients who were CTC 0, CTC + HOXB13 low, and CTC + HOXB13 high, respectively. Median OS were 25.7, 27.8, and 12.1 months whereas the median PFS were 9.0, 7.7, and 3.8 months, respectively. In subgroup analysis among men with CellSearch CTCs ≥5 copies/mL and adjusting for prior abi/enza treatment and Halabi clinical risk score, the multivariate HR for HOXB13 CTC detection was 2.39 (95% CI, 1.06–5.40) for OS and 2.78 (95% CI, 1.38–5.59) for PFS, respectively. Low HOXB13 CTC detection was associated with lower CTC PSA, PSMA, AR-FL, and AR-V7 detection, and more liver/lung metastases (41% vs. 25%). Conclusions: Higher CTC HOXB13 expression is associated with AR-dependent biomarkers in CTCs and is adversely prognostic in the context of potent AR inhibition in men with mCRPC.

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

Donald P. McDonnell

Duke University School of Medicine

UNITED STATES
View details

Daniel J. George

Professor

Duke University

UNITED STATES
View details

Susan Halabi

Duke University

UNITED STATES
View details

John Norris

Associate Research Professor

Duke University

UNITED STATES
View details

Emmanuel S. Antonarakis

-

UNITED STATES
View details

Russell Z. Szmulewitz

Associate Professor

University of Chicago

UNITED STATES
View details

David Nanus

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details